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ExocytosisProtein kinase C epsilon (PKCε) activation controls ﬁbroblast growth factor-2 (FGF-2) angiogenic signaling.
Here, we examined the effect of activating PKCε on FGF-2 dependent vascular growth and endothelial
activation. ψεRACK, a selective PKCε agonist induces pro-angiogenic responses in endothelial cells, includ-
ing formation of capillary like structures and cell growth. These effects are mediated by FGF-2 export to the
cell membrane, as documented by biotinylation and immunoﬂuorescence, and FGF-2/FGFR1 signaling
activation, as attested by ERK1/2-STAT-3 phosphorylation and de novo FGF-2 synthesis. Similarly, vascular
endothelial growth factor (VEGF) activates PKCε in endothelial cells, and promotes FGF-2 export and FGF-2/FGFR1
signaling activation. ψεRACK fails to elicit responses in FGF-2−/− endothelial cells, and in cells pretreated with
methylamine (MeNH2), an exocytosis inhibitor, indicating that both intracellular FGF-2 and its export toward the
membrane are required for the ψεRACK activity. In vivo ψεRACK does not induce angiogenesis in the rabbit cornea.
However, ψεRACK promotes VEGF angiogenic responses, an effect sustained by endothelial FGF-2 release and
synthesis, since anti-FGF-2 antibody strongly attenuates VEGF responses. The results demonstrate that PKCε stimu-
lation promotes angiogenesis and modulates VEGF activity, by inducing FGF-2 release and autocrine signaling.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Epsilon protein kinase C (PKCε), an isozyme of the novel PKCs
subfamily, has a unique biological proﬁle relative to other members of
this family, as its kinase activity invariably stimulates cell functions in
cardiomyocytes, endothelial and other cells [1–4]. Upregulation or
direct activation of PKCε in these cells provides protection against a
range of acute injuries. The translational relevance of the cytoprotective
effects related to these enzymes has been documented in models of
myocardial ischemia/reperfusion and cerebral ischemic injury [3,5,6].
Themolecular basis underpinning the PKCε beneﬁcial effects comprises
several pathways involving primarily mitochondria, fromwhich signals
executing changes in cellular functions originate [7]. Consistent with its, University of Siena, Via Aldo
39 0577 234343.
.Open access under CC BY-NC-ND liceaction onmitochondria, PKCε opposes reactive oxygen species (ROS)me-
diated coronary endothelial dysfunction by modulating endothelial nitric
oxide synthase (eNOS) activity, thus leading to a complete recovery of
endothelial functions, including their proliferative ability and responsive-
ness [4]. PKCε gene ablation in endothelial cells has been reported to
block vascular endothelial growth factor (VEGF)–VEGFR2 signaling [8].
Thus, PKCε appears to play an essential role in maintaining/restoring en-
dothelial cell viability.
Recent work suggests that vascular endothelium integrity is reg-
ulated by a complex interplay of growth factors, particularly ﬁbro-
blast growth factor-2 (FGF-2), a factor involved in the maintenance
and activation of vascular endothelium [9,10]. We investigated the
role of PKCε in endothelial cell activation, determining whether a
connection between PKCε activation and FGF-2 signaling exists for
the control of neovascularization. To selectively activate PKCε we
used the speciﬁc ψεRACK activator or VEGF, while to inhibit PKCε
we used either εV1-2 inhibitor or the silencing of the gene [2,11].
The data presented show that activated PKCε induces FGF-2 release
to the cell surface, which in turn activates the autocrine/paracrine
FGFR1 signaling pathway, promoting endothelial cell growth and
sprouting, and that FGF-2 mobilization into the cell membrane is
crucial for the angiogenic response to VEGF.nse.
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2.1. Reagents
PKCε activator (ψεRACK; ψεRACK-TAT45–57), PKCε inhibitor (εV1-2;
εV1-2-TAT45–57) and scrambled peptide were synthetized as described
[11]. The PKCε inhibitor, εV1-2, was ﬁrst described in 1996, and its
sequence is (EAVSLKPT; PKC14–21) [12]. The PKCε activator, ψεRACK,
was ﬁrst described in 1999, and its sequence is (HDAPIGYD; PKC 85–
92) [13]. Both peptides are conjugated via a Cys S–S bond to a cell per-
meable peptide TAT47–57, which enables the delivery of the peptides
across biological membranes. Peptides are well tolerated and non-
toxic in concentrations above 10 μM, or over 4 orders of magnitude
the efﬁcacious concentration. The peptides are highly selective for
PKCε [14] and they do not affect the activity/function of other PKC
isozymes, even the highly homologous, PKCδ. The peptide inhibitor,
εV1-2, inhibits the interaction between PKCε and its RACK, thus
inhibiting the access of the enzyme to its substrates. The peptide activa-
tor, ψεRACK, inhibits intra-molecular interaction within the enzyme,
thus selectively triggering PKCε activation. In the manuscript, the pep-
tides were delivered at 1 μM. Scrambled peptides do not have these
effects and do not alter PKCε activity [15].
Cell culture reagents and analytical grade chemicalswere fromSigma-
Aldrich, VEGF and FGF-2 from R&D Systems (Minneapolis (MN), USA).
SU5402, U0126, PP1, GM6001 and PpYLTK from Calbiochem (Millipore,
Darmstadt, Germany), andMeNH2was from Sigma-Aldrich. Neutralizing
anti-FGF-2 antibody and anti-VEGFR2 were from Upstate (Millipore),
anti-actin antibody from Sigma-Aldrich, and anti-PKCε was from Santa-
Cruz (CA, USA). Anti-phospho-tyrosine, anti-FGFR1, anti-phospho-
ERK1/2 (Thr202 and Tyr204), anti-ERK1/2, and anti-phospho-STAT-3
Ser727 antibodies were from Cell Signaling Technology (Euroclone,
Pero (MI), Italy).
2.2. Cells
Bovine coronary venular endothelial cells, CVEC, were cultured as de-
scribed [16]. Murine prostate FGF-2−/− and wild type (WT) endothelial
cells were cultured as reported [10]. Cells were used at passages 4–10.
2.3. In vivo angiogenesis
Angiogenesis was studied in the cornea of male New Zealand white
rabbits (n = 15, Charles River) as described [17]. Experiments have
been performed in accordance with the guidelines of the European
Commission for animal care and welfare (Directive 2010/63/EU) and
the National Ethical Committee. Animals were anesthetized by intrave-
nous injection of sodium pentothal (30 mg/kg) and a local anesthetic
(i.e. 0.4% benoxinate) was instilled on the ocular surface just before sur-
gery. To test the role of FGF-2 in VEGF induction of angiogenesis, a fully
competent dose of VEGF (200 ng/pellet) was administered in the pres-
ence of neutralizing anti-FGF-2 antibody (1 μg/pellet) or an equivalent
amount of irrelevant IgG. The effect of ψεRACK on FGF-2-induced angio-
genesis was studied using pellets containing both VEGF (50 ng/pellet)
andψεRACK (200 ng/pellet). The corneaswere observed, anddigital im-
ages were taken with a slit-lamp stereomicroscope.
The following parameters were analyzed in a blind manner and
quantiﬁed with NIH-ImageJ: 1) Budding (tip selection) from limbal
plexus toward the pellet, measured at days 2–3 and shown as budding
index with the following values: 0, absence of buds; 1: 5–10 buds/mm;
2: 10–20 buds/mm; 3: 20–50 buds/mm; 4: 50 buds/mm. 2) Stalk elon-
gation, measured as angiogenic score (number of progressing vessels/
mm2)10 at days 6–8. 3). Maturation or pruning, measured at days
8–10 as pruning index (from 0 to 3) of the rate of reduction/selection
of vessel number. The values reported in the ﬁgures represent means
calculated on the number of replicates indicated for each experimental
setting.2.4. Endothelial cell proliferation
Cell growth was analyzed as described [4]. Brieﬂy, 1.5 × 103 endo-
thelial cells (CVEC or murine WT and FGF-2−/−) were treated with
VEGF (20 ng/ml), ψεRACK (1 μM, 24 h) or FGF-2 (20 ng/ml, 24 h).
Where indicated, cells were pre-treated with selective inhibitors for
30 min or with MeNH2 (10 mM, 1 h). Cells were then ﬁxed in 100%
methanol and stained with Diff-Quik (Biomap snc, Agrate B.za (MI),
Italy). Stained cells were randomly counted in ﬁve ﬁelds in each well
of 96-well plates at 200× magniﬁcation. Results are reported as total
number of cells counted in 5 random high power ﬁelds (counted
cells)/well.
2.5. Wound assay
Endothelial cells were seeded into 24-well plates (1 × 105 cells/
well) and incubated for 24 h to approximately 90% conﬂuence. Follow-
ing serum starvation, cell monolayers were scratched with a sterile tip,
and washed with PBS to remove detached cells. Fresh medium contain-
ing test substanceswas addedwith ARA-C (2.5 μg/ml; SigmaAldrich, St.
Louis, USA) to inhibit cell proliferation. Images of the wound in each
well were acquired from 0 to 9 h under a phase contrast microscope
at 200×. Results are expressed as percentage of healing [18].
2.6. Endothelial cell sprouting in microcarrier culture
Endothelial cells (3 × 105/ml) were incubated with gelatin coated
cytodex 3 microcarriers (Sigma-Aldrich, St. Louis, USA) for 6 h and
then embedded in a ﬁbrin gel. Cell microcarrier complexeswere treated
with ψεRACK (1 μM, 72 h) in the presence or absence of εV1-2 (1 μM),
anti-FGF-2 (6 μg/ml), SU5402 (10 μM) or FGF-2 (20 ng/ml) as indicat-
ed. Micrographs were taken with an inverted phase contrast micro-
scope at 100× magniﬁcation. The area occupied by capillary-like
structures was quantiﬁed as described [4].
2.7. Quantitative RT-PCR
CVEC grown in 10 cm diameter plates were treated with ψεRACK
(1 μM) for the indicated times. Total RNA was extracted using RNeasy
kit (Qiagen, Milan, Italy). Total RNA (1 μg) was reverse-transcribed
using iScript cDNA synthesis kit (Bio-Rad, Segrate (MI), Italy). cDNA
was diluted in water to a ﬁnal concentration of 30 ng/μl. iQSYBER
Green Supermix (Bio-Rad) and the following unlabeled primers (Ap-
plied Biosystems, Foster City (CA) USA) for bovine FGF-2 and β-actin
were used: FGF-2 forward 5′-TCA GCT CTT AGC AGA CAT TGG AAG
AAA AAG-3′, reverse 5′-GGA GTG TGT GCT AAC CGT TAC CTG GCT
ATG-3′, β-actin forward 5′-TGA ATG GAC AGC CAT CAT GGA C-3′,
reverse 5′-TCT CAA GTC AGT GTA CAG GAA AGC-3′. Gene expression
was quantiﬁed by using the threshold cycle (Ct) and the comparative
method (2ˆ−ΔΔCt) as described [19]. Data are reported as fold increase
vs. control.
2.8. Western blot
Western blot was performed as described [4]. CVEC (1 × 106/10 cm
diameter plate) were treated with ψεRACK (1 μM, 15 min) or VEGF
(20 ng/ml) and where indicated, pre-treated with speciﬁc inhibitors
for 30 min. To assess the ɛPKC translocation, cells were treated with
VEGF (20 ng/ml) in presence or in absence of anti-FGF-2 (6 μg/ml)
and then homogenized on ice in Tris–HCl buffer, pH 7.4, containing
1 mM EGTA, 1 mM EDTA, protease and phosphatase inhibitors. Cell ly-
sates were then separated by centrifugation (100,000 ×g, 30 min, 4 °C).
The supernatant containing the cytosolic fraction and the activated PKC
in the pellet were solubilized in lysis buffer containing 1% Triton X-100
followed by homogenization with a 25-gauge needle. An equal amount
of proteins were loaded on SDS/8% PAGE and then transferred to a
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[4]. ERK1/2 and STAT-3 Ser727 phosphorylation was evaluated in cells
treated with ψεRACK. Cell protein extract was electrophoresed in SDS/
10% polyacrylamide (phospho-ERK1/2, phospho-STAT-3 Ser727) or in
SDS/15% gels (FGF-2). Proteins were then blotted onto activatedFig. 1. PKCε activation promotes endothelial cell proliferation and sprouting, upregulating FGF-
itor or in PKCε silenced cells. Scrambled peptide was used as control, all compounds used at
ψεRACK. B. Adherent cell migration at 9 h after treatment with ψεRACK with/without εV1-2 o
and ##p b 0.01 vs. ψεRACK. C. CVEC grown onmicrocarriers treated with ψεRACK (72 h) in the
ering the entire sprouting area (μm2). ***p b 0.001 vs. control; ###p b 0.001 vs. ψεRACK. D. FGF
increase vs. control. *p b 0.05, **p b 0.01 and ***p b 0.001 vs. time 0. E. FGF-2 expression was
18 h). Data are reported as arbitrary densitometric units (A.D.U.) *p b 0.05 and ***p b 0.001
30 h). Data are reported as pg/ml normalized by total mg protein. **p b 0.01 and ***p b 0.001nitrocellulose membranes, incubated overnight with the antibodies and
antigen–antibody complexes were detected with enhanced chemilumi-
nescence kit (Bio-Rad). Band intensity was measured by scanning densi-
tometry and the results were normalized to total ERK1/2 (for phospho-
ERK1/2) or β-actin (for phospho-STAT-3 Ser727 and FGF-2).2 expression. A. ψεRACK-induced proliferation in CVEC in presence/absence of PKCε inhib-
1 μM, 24 h. Data represent counted cells/well. ***p b 0.001 vs. control; ###p b 0.001 vs.
r in PKCε silenced cells. The graph shows % change in wound area. **p b 0.01 vs. control
presence/absence of εV1-2 (72 h). Sprouting score represents the mean of grid units cov-
-2mRNA expression in response to ψεRACK (1 μM, 15 min to 30 h). Data are shown as fold
measured in the cell lysates by Western blot. Cells were treated with ψεRACK (1 μM, 3 to
vs. time 0. F. FGF-2 release in CVEC media. Cells were treated with ψεRACK (30 min to
vs. control; n = 3.
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Cells pretreated with the indicated inhibitors were stimulated with
ψεRACK (15 min). Cell lysates were immunoprecipitated with anti-
FGFR1 antibody (4 μg/300 μg total proteins) as described [4]. Immuno-
precipitates were analyzed byWestern blot as described above. Results
were normalized to FGFR1.
2.10. ELISA
CVEC (1 × 106 cells) were cultured for 24 h after adherence. Cell me-
dium was collected after 48 h and lyophilized. The lyophilized media
were diluted in an equal amount of PBS, and then analyzed by FGF-2
ELISA kit (R&D System, Minneapolis MN, USA) following manufactured
instructions.
2.11. siRNA design and transfection
The siRNA sequence targeting bovine PKCε (siɛPKC) (5′-UCAAA
UGACAAGGCCUUCCgg-3′) corresponding to region 1224–1242
(Accession NM_001111120), was synthetized by Ambion (Austin
(TX), USA) [8]. Control siRNA (siCtrl) is a random siRNA provided
by Ambion. CVEC were transfected 24 h after plating, using siRNA
(1.6 μg) complexed with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) (ﬁnal concentration 0.125% v/v). The transfection reagent was
removed after 5 h by changing the growth medium. Cultures were
used for experiments 72 h after transfection.
2.12. Immunoﬂuorescence and confocal microscopy
FGF-2 localization at cell surface was visualized by confocal micros-
copy. Endothelial cells (2 × 104) were seeded onto 1-cm round glass
coverslips. The cells were washed with NaCl 2 M pH4, treated with
MeNH2 (10 mM, 1 h) and thenwithψεRACK (1 μM, for the time indicat-
ed). Cells were ﬁnally ﬁxed in 4% paraformaldehyde in PBS without
permeabilization. Nonspeciﬁc binding sites were blocked with 3%
bovine serum albumin (BSA) and the cells were incubated for 2 h
with monoclonal anti-FGF-2 antibody (10 μg/ml in PBS containing
0.5% BSA). Cells were then washed, incubated for 1 h with ﬂuorescein
isothiocyanate labeled goat anti-mouse IgG antibody (10 μg/ml in PBS
with 0.5% BSA, Sigma-Aldrich). The coverslips were mounted with
Mowiol 4-88 (Calbiochem, La Jolla (CA), USA) and pictures of stained
cells were taken using a confocal microscope (Zeiss LSM700).
2.13. Cell surface protein biotinylation
Conﬂuent cells in T75 cm2 ﬂasks were serum starved and then
washed with NaCl 2 M pH 4 to elute FGF-2 from the cell surface [20].
Following incubation with MeNH2 (10 mM, 1 h) and with ψεRACK for
indicated time, the cells were labeled with EZ-Link Sulfo-NHS-SS-Biotin,
a thiol-cleavable amine-reactive biotinylation reagent (Thermo Scientif-
ic, MA, USA) following themanufacturer's instructions. After lysis with a
mild detergent, a NeutrAvidin Agarose column was used to separate
the biotinylated proteins, which were eluted with Laemmli bufferFig. 2. FGF-2 mediates the proangiogenic activity of PKCε. A. Proliferation of CVEC treated with
###p b 0.001 vs.ψεRACK. B. Cellmigrationmeasured as described in Fig. 1 legend. Cellswere pretre
wasmeasured as % reduction inwound area. **p b 0.01 vs. control and ##p b 0.01 vs.ψεRACK. C. C
antibody (6 μg/ml, 72 h). Sproutingwasmeasured as described in Fig. 1 legend. ***p b 0.001 vs. con
2−/− endothelial cells (FGF-2−/− EC) treatedwithψεRACK or FGF-2 (20 ng/ml) for 24 h. **p b 0.01
(20 ng/ml) treatment (72 h). Cell sprouting was quantiﬁed as described in Fig. 1 legend. ***p b 0.
ψεRACK. ***p b 0.01 vs. control and ###p b 0.001 vs.ψεRACK. G. Effect of SU5402 (10 μM, 30 min)
vs. ψεRACK.containing 50 mmol/L DTT. FGF-2 was detected by Western blot as
described above.2.14. Statistical analysis
Results are expressed as means ± S.D. of at least three experiments
with triplicate samples. Statistical analysis was performed using the
Student's t-test or analysis of variance when appropriate, followed by
the Bonferroni test. A value of p b 0.05 was considered statistically
signiﬁcant.3. Results
3.1. PKCε activation induces endothelial cell proliferation and sprouting
Our previous observations have shown that PKCε activation pro-
motes the survival of coronary venular endothelial cells (CVEC) [4].
We therefore investigated endothelial cell proliferation and capillary
like structure formation using the selective PKCε peptide agonist
(ψεRACK) and antagonist (εV1-2) or the siRNA for PKCε [8,11]. ψεRACK
increased cell proliferation and migration by about 75% (Figs. 1A and
B, and 1S). Either εV1-2 or the si-PKCε reversed these effects (Figs. 1A
and B, and 1S), while a control scrambled peptide exerted no effect
(Fig. 1A). Next, we examined endothelial cell capillary like structure for-
mation. ψεRACK treatment of CVEC grown on microcarriers embedded
in 3D ﬁbrin gel (72 h) induced a ten-fold increase in sprouting relative
to control, untreated cells. Co-treatment with εV1-2 abolished
ψεRACK-induced cell sprouting, but not basal sprouting (Fig. 1C).3.2. FGF-2 mediates the pro-angiogenic activity of PKCε
To study the mechanism underpinning the proangiogenic effect of
ψεRACK, we examined its ability to activate the expression of FGF-2, a
factor known to promote autocrine proangiogenic signaling in endothe-
lial cells [21]. ψεRACK elicited an early (3 h) increase of FGF-2 mRNA
(Fig. 1D), followed by a later rise in FGF-2 protein between 6 and 18 h
(Fig. 1E), and extracellular FGF-2 release detectable starting from 18 h
(Fig. 1F).
To study the role of FGF-2 in ψεRACK mediated cell functions, we
suppressed FGF-2 signaling using different approaches. Treatment
with anti-FGF-2 antibody abolished ψεRACK stimulated cell prolifera-
tion, migration and capillary like structure formation (Figs. 2A, B, C
and 1S). Consistently, ψεRACK failed to induce those effects in endothe-
lial cells genetically deﬁcient in FGF-2 (FGF-2−/−) (Figs. 2D and E), al-
though these cells responded to exogenous FGF-2 (Figs. 2D and E),
while it promotedwild type endothelial cell proliferation and sprouting
(Figs. 2D and E). In addition, ψεRACK effects were abolished by SU5402,
an inhibitor of ﬁbroblast growth factor receptor 1 (FGFR1) activation
(Figs. 2F, G and 1S). Similar results were obtained with other type of
vascular endothelial cells (data not shown).
These results indicate that the ψεRACK induced endothelial cell pro-
liferation and sprouting depend on autocrine FGF-2 signaling.ψεRACK (24 h) with/without anti-FGF-2 antibody (6 μg/ml, 24 h). ***p b 0.001 vs. control;
atedwith anti FGF-2 antibody (6 μg/ml, 30 min) and stimulatedwithψεRACK (9 h).Migration
VEC grown onmicrocarriers treatedwithψεRACK (72 h) in the presence/absence of anti FGF-2
trol; ###p b 0.001 vs.ψεRACK. D. Proliferation ofwild type endothelial cells (WTEC) and FGF-
or ***p b 0.001 vs. control. E. Sprouting ofWTEC and FGF-2−/− EC followingψεRACK or FGF-2
001 vs. control. F. Effect of SU5402 (10 μM, 24 h) on the proliferation of CVEC stimulated with
on themigration of CVEC stimulatedwithψεRACK (9 h). **p b 0.01 vs. control and##p b 0.01
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pendent mechanism
In order to deﬁne the pathophysiological relevance of PKCε activa-
tion, we determined its role in VEGF mediated angiogenesis. It is
known that the angiogenic activity of VEGF relies in part on FGF-2 avail-
ability/signaling [22,23]. It has also been reported that εPKC in endothe-
lial cells mediates VEGF/VEGFR2 angiogenic signaling [8]. Therefore,
based on the above results, we investigated whether ψεRACK contrib-
utes to VEGF angiogenic responses by increasing FGF-2 availability.
We ﬁrst used the in vivomodel of angiogenesis in the rabbit cornea to
study the contribution of endogenous FGF-2 to angiogenesis induced
by VEGF. For this purpose, we inhibited FGF-2 in corneal tissue with
neutralizing anti-FGF-2 antibody. Implantation of VEGF-releasing
pellets (200 ng/pellet) induced the outgrowth of buds from limbal
capillaries within 2–3 days (Figs. 3A and 2S A, panel 1). During the
ﬁrst week, the vascular buds evolved into functional vessels contribut-
ing to vessel elongation (Figs. 3A and 2SA, panel 2).Morphometric anal-
ysis showed that after 8–10 days, vessel remodeling proceeded through
the selection of progressing vessels by pruning of non-efﬁcient ones,
and growth of the selected vessels toward the angiogenic stimulus
(Figs. 3A and 2S A, panel 3).Fig. 3. PKCε promotes VEGF induction of angiogenesis in vivo by a FGF-2 dependentmechanism
antibody (1 μg/pellet), and VEGF (50 ng/pellet) in the absence/presence of ψεRACK (200 ng/pel
panel 1), vessel elongation,measured as angiogenic score (6 days, panel 2), and vesselmaturati
C. Representative images of neovascularization at 10 days after implantation of VEGF releasing
VEGF 50 ng/pellet alone (3) or in the presence of ψεRACK (4). Pellet implants (P) are marked.Consistent with previous ﬁndings, when VEGF was co-released with
neutralizing anti-FGF-2 antibody (1 μg/pellet) into the cornea, the num-
ber of newly formed vessels was signiﬁcantly reduced (Figs. 3A, C, panel
2 and 2S B) indicating the requirement of FGF-2 for VEGF induced
angiogenesis.
Therefore, we analyzed the angiogenic effect of ψεRACK in the ab-
sence or presence of a suboptimal dose of VEGF (50 ng/pellet). ψεRACK
alone (200 ng/pellet) failed to induce a neovascular response (data not
shown). Similarly, VEGF (50 ng/pellet) induced a delayed and modest
vascularization, detectable at 10 days from pellet implantation
(Figs. 3B, C, panel 3 and 2S C). However, the simultaneous delivery of
ψεRACK and VEGF (50 ng/pellet) resulted in a higher number of buds
and progressing vessels at the early stages of angiogenesis (Figs. 3B
black columns, C, panel 4, and 2S D). Vessel maturationwas accelerated,
as compared to 50 ng VEGF alone; the effect being similar to that in-
duced by 200 ng VEGF (Figs. 3A and C). These results indicate that
FGF-2 mobilization in the cornea stroma was crucial for the angiogenic
response to VEGF, and that PKCε activation contributes toVEGF-induced
angiogenesis in vivo.
Further, to investigate whether PKCε contributed to VEGF angiogen-
ic activity via FGF-2 increased availability, we performed in vitro exper-
iments with cultured endothelial cells. First, we examined the role of. A and B. VEGF (200 ng/pellet) plus IgG in the absence/presence of neutralizing anti-FGF-2
let), respectively.Morphometric data of vessel sprouting, shown as budding index (3 days,
on/pruning quantiﬁed as pruning index (at 10 days, panel 3). Data aremeans of 3 implants.
pellet (200 ng/pellet) in the presence of irrelevant IgG (1) or anti FGF-2 antibody (2), and
113M. Monti et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 107–117FGF-2 in controlling VEGF activity on endothelial cells. In CVEC, admin-
istration of neutralizing FGF-2 antibody abolished VEGF-induced cell
growth andmigration (Figs. 3SA and B); however, VEGF failed to induce
cell growth in FGF-2−/− endothelial cells (Fig. 3S C). To assess the role of
PKCε in the interaction between VEGF and FGF-2, we examined wheth-
er VEGF induces PKCε activation bymeasuring its translocation from the
cytosol to the plasma membrane in cultured CVEC. VEGF induced rapid
(10 min) PKCε translocation (Fig. 3S D), whichwas not affected by anti-
FGF-2 antibody (Fig. 3S E). Conversely, when εPKC activation was
suppressed either by PKCε siRNA or by εV1-2, VEGF failed to promote
cell growth and migration (Figs. 3S F and G). All together, these results
show that PKCε activation following VEGF stimulation is instrumental
for VEGF functional effects.
3.4. ψεRACK upregulates FGF-2 expression in endothelial cells
Next we investigated the molecular events underlying ψεRACK-
induced FGF-2 expression in endothelial cells. As previously reported,Fig. 4. ψεRACK activates ERK1/2-STAT-3 signaling through FGF-2. A. ERK1/2 activation by ψεRAC
withU0126 (10 μM, 30 min) and incubatedwith PKCε (15 min). ***p b 0.001 vs. control; ###p
of U0126 (10 μM, 18 h) or STAT-3 inhibitor (PpYLTK, 10 μM, 18 h). ***p b 0.001 vs. control;
pretreated with anti FGF-2 antibody (6 μg/ml) or SU5402 (10 μM, 30 min) and stimulated wit
in FGF-2−/− cells treated with either ψεRACK or FGF-2 (20 ng/ml, 15 min). ***p b 0.01 vs. contendothelial FGF-2 synthesis is regulated by a signaling cascade involving
ERK1/2 and STAT-3 activation [24]. ψεRACK (15 min) increased ERK1/2
(Fig. 4A) and STAT-3 Ser727 phosphorylation (Fig. 4B) and,most impor-
tantly, induced a three-fold increase in FGF-2 expression (Fig. 4C). All
these events were inhibited by the MEK (U0126 10 μM), or STAT-3
(PpYLTK 25 μM) inhibitors (Figs. 4B and C), as well as by anti-FGF-2
antibody (Fig. 4D). In addition,ψεRACK failed to elicit ERK1/2 phosphor-
ylation in FGF-2−/− endothelial cells (Fig. 4E), strongly suggests
that FGF-2/FGFR1 mediates PKCε activation of the pro-angiogenic
ERK1/2-STAT-3 signaling pathway.
3.5. ψεRACK promotes FGF-2 translocation to the endothelial cell
membrane
FGF-2 lacks a signal peptide for secretion through the classical ER–
Golgi pathway, and is released by cells through an exocytosis mecha-
nism [25]. Therefore, based on the rapid effect of ψεRACK in promoting
ERK1/2 activation (Fig. 4A), we examined whether PKCε activationK (15 min). **p b 0.001 vs. control. B. STAT-3 Ser727 phosphorylation in CVEC pretreated
b 0.01 vs.ψεRACK. C. FGF-2 expression inCVEC treatedwithψεRACK (18 h) in the presence
###p b 0.001 vs. ψεRACK. D. Western blot analysis of ERK1/2 phosphorylation in CVEC
h ψεRACK (15 min). ***p b 0.01 vs. control and #p b 0.01 vs. ψεRACK. E. ERK1/2 activation
rol.
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interaction with cell surface receptors [26]. To investigate this hypothe-
sis, we characterized FGF-2 release induced by ψεRACK in the presence
or absence of methylamine (MeHN2), an inhibitor of exocytosis that
blocks FGF-2 release [25]. For this purpose, we ﬁrst removed cell surface
associated FGF-2 by washing the cells with 2.0 M NaCl at pH 4.0. We
then pretreated the cells with MeHN2 (10 mM) or control vehicle for
1 h, followed by addition of ψεRACK for 30 min, and characterized cell
surface associated FGF-2 by immunoﬂuorescence staining of non-
permeabilized cells with anti-FGF-2 antibody. As shown in Fig. 5A,
ψεRACK increased the amount of cell surface associated FGF-2 (panel
b) compared to the control condition (panel a), and this effect was
abolished by MeHN2 (panel c and d), indicating that ψεRACK inducesFig. 5. PKCε induces FGF-2 release. A. Immunoﬂuorescence analysis of FGF-2 in untreated CVEC (
withMeNH2 (10 mM, 1 h) and thenwithψεRACK (30 min) (d). Panels (e), (f) and (g) represent
permeabilized cells), respectively. B. Western blot analysis of biotinylated FGF-2 in CVEC treate
1 h). ***p b 0.001 and ¶¶¶p b 0.001 vs. control, and ###p b 0.001 vs. ψεRACK. C. Proliferation
***p b 0.001 vs. control; ###p b 0.001 vs. ψεRACK. D. Migration of CVEC treated for 9 h with
vs. control and ###p b 0.001 vs. ψεRACK. E. FGFR1 activation in CVEC pretreated with M
###p b 0.001 vs. ψεRACK.rapid release of FGF-2 from the cells. Further, we biotinylated cell sur-
face proteins following the ψεRACK and MeNH2 treatment, and quanti-
ﬁed the amount of biotinylated FGF-2. As shown in Fig. 5B, this
method revealed the presence of both high and low molecular weight
forms of FGF-2. ψεRACK treatment increased the levels of all FGF-2
forms, and MeNH2 abolished this effect (Fig. 5B). MeNH2 also abolished
ψεRACK-induced up-regulation of cell proliferation and migration
(Figs. 5C, D and 1S), and FGFR1 phosphorylation (Fig. 5E). Conversely,
administration of exogenous FGF-2 to cell pretreated with MeNH2
reversed cell migration.
VEGF, upstream to PKCε signaling, also promoted the FGF-2 translo-
cation to the cell membrane, and either PKCε siRNA or by εV1-2
inhibited VEGF-induced FGF-2 export (Figs. 4S A and B). These ﬁndingsa), CVEC treatedwithψεRACK for 30 min (b), orMeNH2 (10 mM) for 1 h (c), or pretreated
negative (e: only secondary antibody; f: FGF-2−/− cells) and positive controls (g:ﬁxed and
d with ψεRACK (as above) in the presence or absence of MeNH2 (10 mM, pretreatment for
of CVEC treated with MeNH2 (10 mM, 1 h) and then with ψεRACK (24 h). ¶p b 0.05 or
ψεRACK or FGF-2 with or without 1 h pretreatment with MeNH2. ¶p b 0.05 or **p b 0.01
eNH2 (10 mM, 1 h) and treated with ψεRACK (15 min). ***p b 0.001 vs. control and
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face, promoting interaction with its cell membrane receptors and the
ensuing activation of pro-angiogenic functions. We then investigated
the kinetics of FGF-2 release in response toψεRACK or VEGF by immuno-
ﬂuorescence (Figs. 6A and 4S A and B) and biotinylation of cell surface
proteins (Fig. 6B). VEGF/ψεRACK system elicited a biphasic FGF-2 release
response: an early phase (at 15–30 min) and a late phase, at 9–18 h
after VEGF or ψεRACK administration (Figs. 6A, B and 4S A and B). Pre-
treatment with MeNH2 blocked FGF-2 release at both phases (Figs. 6A
and B).
We also explored whether Src kinase and metalloproteinases
(MMPs) were involved in PKCε effects on FGF-2 release and activity
[26]. Since their respective inhibitors (PP1, or GM6001) had no effectFig. 6. PKCεmobilizes FGF-2 by a Src/metalloproteinases independentmechanism. A. Immunoﬂ
indicated times, or MeNH2 (10 mM, 1 h), or pretreated with MeNH2 (10 mM, 1 h) and then wi
ψεRACK (9 to 24 h) in the presence or absence of MeNH2 (10 mM, pre-treatment 1 h). C. FGFR1
(15 min). ***p b 0.001 vs. control. D. FGFR1 phosphorylation in CVEC pretreated with GM6001on ψεRACK-induced FGFR1 phosphorylation (Figs. 6C and D), we con-
clude that neither signal is involved in the FGF-2mediated mechanisms
activated by PKCε.
Thus, these data showed that ψεRACK induces FGF-2 release to the
endothelial cell surface, leading to FGF-2 autocrine signaling and angio-
genesis (Fig. 7).
4. Discussion
The involvement of PKC isozymes in endothelial/cardiomyocytes
function and angiogenesis is well documented [4,27,28]. Data in the lit-
erature demonstrate that PKCε deletion contributes to vascular dys-
function decreasing endothelial cell and/or smooth muscle cellsuorescence analysis of FGF-2 in untreated CVEC (time 0), CVEC treatedwith ψεRACK for the
th ψεRACK (9 to 18 h). B.Western blot analysis of biotinylated FGF-2 in CVEC treated with
phosphorylation in CVEC pretreated with PP1 (500 nM, 30 min) and exposed to ψεRACK
(1 μM, 30 min) and treated with ψεRACK (15 min). ***p b 0.001 vs. control.
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investigated the role of PKCε in angiogenesis, using two short peptides
that interact speciﬁcally with this isozyme, producing either its activa-
tion (ψεRACK) or its inhibition (εV1-2). The use of these pharmacologi-
cal tools avoids the interference of other PKC isozymes with similar
structural features but often opposing roles [31–33]. Our results show
that selective PKCε activation byψεRACK induces endothelial cell activa-
tion through a novel mechanism (schematically depicted in Fig. 7).
Increase in cell growth, migration and capillary like sprouting, indicates
that activated PKCε elicits a typical angiogenic phenotype. Speciﬁcally,
we ﬁnd that ψεRACK promotes FGF-2 translocation to the cell surface,
an event that triggers the autocrine–paracrine FGF-2/FGFR1 loop, that,
in turn, sustains the VEGF-driven angiogenesis. FGF-2 represents an
example of unconventional, ER–Golgi independent secretion as it is
released from cells by exocytosis [25], although its mechanism remains
elusive. Evidence that PKCε and FGF-2 are functionally associated toFig. 7. FGF-2 exocytosis in endothelial cells by PKCε activation. (A) PKCε activation by the
selective ψεRACK or the VEGF/VEGFR2 signaling induces the exocytosis of FGF-2 into the
extracellular matrix and activation of the proangiogenic FGFR1 signaling pathway.
Heparan sulfate proteoglycans are coreceptorswith FGFR1. (B) Blockadewith PKCε antag-
onist or with antibodies against FGF-2 inhibits the FGFR1/ERK1/2/STAT signaling and the
subsequent proliferation and migration of the endothelial cells.produce endothelial activation through FGF-2/FGFR1 autocrine cycle
activation, underpins all the functional effects here reported (cell
sprouting, proliferation and migration). The key event is the ability of
activated PKCε to promote the export of intracellular FGF-2 toward the
membrane (Fig. 7). The demonstration that ψεRACK promotes FGF-2
exocytosis is seen in the FGF-2 immunoﬂuorescence tethered to the
membrane, and by its inhibition by the exocytosis blocker MeNH2.
Further, evidence was found in experiments on endothelial cells, either
silenced for PKCε or knocked down for FGF-2 gene (FGF-2−/−). These
cells are unresponsive to both VEGF andψεRACK, as they fail to elicit func-
tional responses. This clearly demonstrates that PKCε stimulation
promotes endothelial cell activation through FGF-2 signaling.
FGF-2 exocytosis appears crucial for triggering the known autocrine
loop FGF-2-FGFR1, a cycle characterized by the phosphorylation of
FGFR1 occurring within minutes following ψεRACK stimulation (15–
30 min). The FGFR1 phosphorylation, in turn, induces the activation of
downstream intracellular signals such as ERK1/2 and STAT-3, enhancing
de novo FGF-2 synthesis, and its delayed release into the medium (18 h
by ELISA) (Fig. 7). Theseﬁndings are consistentwith thewell-established
notion that, because of its high positive charge and heparan sulfate afﬁn-
ity, FGF-2, that is rapidly released from the cells after PKCε stimulation is
immediately sequestered on the cell surface, and released into the
medium when all the binding sites are saturated. This sequence of
membrane and cytosolic signals is sensitive to appropriate inhibitors
such as neutralizing FGF-2 antibody or the FGFR1 inhibitor (SU5402),
as well as inhibitors of intermediate signals. Therefore, these data show
that the stimulation of the FGF-2/FGFR1 signaling pathway is a necessary
condition for the development of the angiogenic phenotype following
PKCε activation.
The biological functions of FGF-2 have so far been reported to be
controlled at the level of gene expression and mobilization from the
extracellular matrix, but it is unclear whether secretion can regulate
FGF-2 function activities [34]. However, recently it has been reported
that activation of the inﬂammasome stimulates FGF-2 secretion in ﬁbro-
blasts, suggesting that secretion could also be a mechanism for the con-
trol of FGF-2 activity under normal conditions [35].
Studies have indicated a link between FGF-2 and VEGF signaling,
showing that FGF-2 is a requirement for VEGF-induced neovascu-
larization, as it regulates VEGF receptor expression [22,23,36]. The pres-
ent results, showing that VEGF administration to endothelial cells
promotes in sequence PKCε activation, and FGF-2 exocytosis and its sig-
naling, provide evidence for the functional link between these growth
factors. They also provide a rationale for the somewhat paradoxical inhi-
bition exerted by the neutralizing FGF-2 antibody on VEGF-induced an-
giogenic responses in vitro and in vivo. These ﬁndings also explain how
ψεRACK, delivered concomitantly with a minimally effective dose of
VEGF into the avascular rabbit cornea, produces robust angiogenesis, af-
fectingmostly the budding and stalk elongation of neo-vessels, and also
accounts for the inhibition exerted by neutralizing FGF-2 antibody.
Here we show that ψεRACK-mediated FGF-2 exocytosis activates the
autocrine/paracrine FGF-2/FGFR1 signaling in endothelial cells and,
in turn, sustains the paracrine VEGF mediated angiogenic activity.
Conceivably, PKCε stimulation by ψεRACK-like pharmacological agents
represents a potential complementary strategy for pharmacological ap-
proaches aimed to increase vascularization in damaged tissues through
the local administration of angiogenic factors [37].
In conclusion, ψεRACK-induced activation of coronary endothelial
cells, combined with its protective effects on cardiomyocytes [5], pro-
vides an integratedmechanism for repairing/restoring cardiac functions
in diseases in which endothelial dysfunction is the main pathogenic
mechanism.
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